A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Medical Monitor
- Phone Number: +86 21 68810689
- Email: study898@fibrogen.cn
Study Locations
-
-
-
Baoding, China
- Affiliated Hospital of Hebei University
-
Beijing, China
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Beijing, China
- Peking University Cancer Hospital
-
Beijing, China
- Capital Medical University Chest Hospital
-
Changchun, China
- Jilin cancer hospital
-
Changsha, China
- Hunan Cancer Hospital
-
Chengdu, China
- Sichuan Cancer Hospital
-
Chongqing, China
- Chongqing Bishan People's Hospital
-
Chongqing, China
- The Second Affiliated Hospital of Third Military Medical University (Xinqiao Hospital)
-
Deyang, China
- Deyang People's Hospital
-
Foshan, China
- The First People's Hospital of Foshan
-
Fuzhou, China
- Fujian Medical University Union Hospital
-
Guangzhou, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University - Gynecologic Oncology Department
-
Guangzhou, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University - Oncology Department
-
Hangzhou, China
- Zhejiang Cancer Hospital
-
Hangzhou, China
- Hangzhou Cancer Hospital
-
Harbin, China
- Harbin Medical University Cancer Hospital
-
Hefei, China
- Anhui Cancer Hospital
-
Jiangxi, China
- Jiangxi Cancer Hospital
-
Jinan, China
- Shandong First Medical University Cancer Hospital
-
Lanzhou, China
- The Second Hospital of Lanzhou University
-
Nanjing, China
- Jiangsu Province Hospital
-
Nanning, China
- The People's Hospital of Guangxi Zhuang Autonomous Region
-
Neijiang, China
- Neijiang Second People's Hospital
-
Ningbo, China
- Ningbo First Hospital
-
Pingxiang, China
- Jiangxi Pingxiang People's Hospital
-
Qingdao, China
- The Affiliated Hospital of Qingdao University
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
Shanghai, China
- Shanghai Chest Hospital
-
Shanghai, China
- Shanghai Fifth People's Hospital
-
Shenyang, China
- Liaoning Cancer Hospital & Institute
-
Shenyang, China
- The First Hospital of China Medical University - Oncology Department Breast Cancer Group
-
Shenyang, China
- The First Hospital of China Medical University - Oncology Department Lung Cancer Group
-
Shenzhen, China
- Peking University Shenzhen Hospital
-
Taiyuan, China
- Shanxi Cancer Hospital
-
Wuhan, China
- Union Hospital Tongji Medical College, Huazhong University of Science and Technology
-
Wuhan, China
- University of Science and Technology
-
Wuhan, China
- Wuhan Fourth Hospital
-
Xi'an, China
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xinjiang, China
- Cancer Hospital of Xinjiang Medical University
-
Xuzhou, China
- Xuzhou Central Hospital
-
Yantai, China
- Yantai YuHuangDing Hospital
-
Yinchuan, China
- General Hospital of Ningxia Medical University
-
Zhengzhou, China
- Henan Cancer Hospital
-
Zhuzhou, China
- Zhuzhou Central Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Diagnosis of non-myeloid malignancy, by histological or cytological confirmation.
- Anemia related to myelosuppressive chemotherapy, defined as Hb ≤100 g/L at screening with documented participant's Hb level decrease ≥10 g/L after the initiation of chemotherapy as judged by the investigator.
- Planned concurrent treatment of cancer (myelosuppressive chemotherapy) for at least 8 additional weeks.
- Body weight ≥40 kg.
- Eastern Cooperative Oncology Group (ECOG) performance status of 1 or 2.
- Ferritin ≥50 nanograms (ng)/milliliter (mL) and transferrin saturation (TSAT) ≥10%.
Key Exclusion Criteria:
- Participants with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
- Participants who are only receiving hormonal products, biological products, novel immunosuppressive products (such as programmed cell death protein-1 [PD-1] and programmed death-ligand 1 [PD-L1] checkpoint inhibitors) or targeted biological or radiation therapy to treat/manage their cancer, however if chemotherapy is co-administered with these products, then it is acceptable to enroll the participant.
- Participants with hematocrit (HCT) ≥36%.
- Participants who have received an RBC transfusion or ESA within 4 weeks of randomization.
- Thromboembolic event (including but not limited to deep vein thrombosis [DVT], pulmonary embolism, myocardial infarction, stroke, transient ischemic attack [TIA] within previous 6 months of screening.
- Clinically significant anemia due to other etiologies such as iron deficiency, vitamin B12 or folate deficiency, autoimmune anemia, hemolysis, hemorrhage, or hereditary anemia such as sickle cell anemia or thalassemia.
- The Investigator judges that the participant will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, addiction, or any other relevant medical conditions.
Note: Other inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Roxadustat
Participants will receive roxadustat, administered orally 3 times per week (TIW) for 12 weeks to achieve Hb levels of 100-120 g/L.
The starting dose will be based on the participant's weight group.
The maximum dose for individual participants may not exceed 3.5 milligrams (mg)/kilogram (kg) or 400 mg TIW whichever is lower.
|
Roxadustat will be administered per dose and schedule specified in the arm description.
Other Names:
|
|
Active Comparator: SEPO®
Participants will receive SEPO®, injected subcutaneously TIW for 12 weeks to achieve Hb levels of 100-120 g/L.
The starting dose will be 150 international units (IU)/kg subcutaneously TIW.
|
SEPO® will be administered per dose and schedule specified in the arm description.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hemoglobin (Hb) Level From Baseline to the Level Averaged Over Weeks 9-13
Time Frame: Baseline, Weeks 9 through 13
|
Hb levels measured from Weeks 9 through 13 will be averaged in order to provide a single measure for comparison to the baseline Hb levels.
|
Baseline, Weeks 9 through 13
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants who Achieve a ≥10 Grams (g)/Liter (L) Increase in Hb From Baseline Through Week 13
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale Score Averaged Over Weeks 9-13
Time Frame: Baseline, Weeks 9 through 13
|
FACT-An subscale scores will be averaged over Weeks 9 through 13 in order to provide a single measure for comparison to the baseline score.
|
Baseline, Weeks 9 through 13
|
|
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Subscale Score Averaged Over Weeks 9-13
Time Frame: Baseline, Weeks 9 through 13
|
FACIT-F subscale scores will be averaged over Weeks 9 through 13 in order to provide a single measure for comparison to the baseline score.
|
Baseline, Weeks 9 through 13
|
|
Percentage of Participants who Require Dose Reduction or a Dose-Hold of Chemotherapy Due to Anemia
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Change in Hb From Baseline up to 4 Weeks After the Last Dose of Chemotherapy During the Treatment Period
Time Frame: Baseline up to 4 weeks after the last dose of chemotherapy (up to Week 16)
|
Baseline up to 4 weeks after the last dose of chemotherapy (up to Week 16)
|
|
|
Change in Hb From Baseline Through Week 9
Time Frame: Baseline through Week 9
|
Baseline through Week 9
|
|
|
Change in Hb From Baseline Through Week 13
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Percentage of Participants who Achieve a ≥ 15 g/L Increase in Hb From Baseline Through Week 13
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Percentage of Participants who Achieve Hb Levels ≥ 110 g/L From Baseline Through Week 13
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Percentage of Participants who Achieve an Increase in Hb of 15 g/L or Attaining a Hb of 110 g/L From Baseline Through Week 13
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Time to First RBC Transfusion
Time Frame: Baseline up to Week 13
|
Baseline up to Week 13
|
|
|
Percentage of Participants Requiring 1 or More RBC Transfusion
Time Frame: Baseline up to Week 13
|
Baseline up to Week 13
|
|
|
Number of RBC Transfusions Adjusted for Exposure From Baseline Through Week 13
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Percentage of Participants who Require RBC Transfusion as Medical Intervention and/or Erythropoiesis-Stimulating Agent (ESA) as a Rescue Agent
Time Frame: Baseline through Week 13
|
Baseline through Week 13
|
|
|
Percentage of Participants who Require Red Blood Cell (RBC) Transfusion or Hb <60 g/L or with any Hb< 60 g/L From Week 5 Through Week 13
Time Frame: Week 5 through Week 13
|
Week 5 through Week 13
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FGCL-4592-898
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.